Zealand Pharma & Roche Partner to co-develop petrelintide for obesity treatment
Case News
Plesner has advised Zealand Pharma A/S ("Zealand Pharma") on its collaboration and license agreement with Roche, to develop petrelintide for the treatment of overweight and obesity in the biggest-ever obesity drug deal.
Zealand Pharma has entered into a collaboration and license agreement with Roche to co-develop and co-commercialise petrelintide for the treatment of overweight and obesity.
Under the terms of the agreement, Zealand Pharma and Roche will co-develop and co-commercialise petrelintide and potential combination products, and Zealand Pharma will receive upfront cash payments of USD 1.65 billion, as well as potential milestone payments, for a total consideration of up to USD 5.3 billion
Plesner is grateful to have advised Zealand Pharma, together with Goodwin LLP, on this strategically important transaction.
Plesner's core team on the transaction included Thomas Holst Laursen, Mikkel Rostock-Jensen, and Nikolai Seltoft.